Roy Sudeshna, Šileikytė Justina, Neuenswander Benjamin, Hedrick Michael P, Chung Thomas D Y, Aubé Jeffrey, Schoenen Frank J, Forte Michael A, Bernardi Paolo
University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, KS, 66049, USA.
Division of Chemical Biology and Medicinal Chemistry and the Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.
ChemMedChem. 2016 Feb 4;11(3):283-8. doi: 10.1002/cmdc.201500545. Epub 2015 Dec 23.
Persistent opening of the mitochondrial permeability transition pore (PTP), an inner membrane channel, leads to mitochondrial dysfunction and renders the PTP a therapeutic target for a host of life-threatening diseases. Herein, we report our effort toward identifying small-molecule inhibitors of this target through structure-activity relationship optimization studies, which led to the identification of several potent analogues around the N-phenylbenzamide compound series identified by high-throughput screening. In particular, compound 4 (3-(benzyloxy)-5-chloro-N-(4-(piperidin-1-ylmethyl)phenyl)benzamide) displayed noteworthy inhibitory activity in the mitochondrial swelling assay (EC50 =280 nm), poor-to-very-good physicochemical as well as in vitro pharmacokinetic properties, and conferred very high calcium retention capacity to mitochondria. From the data, we believe compound 4 in this series represents a promising lead for the development of PTP inhibitors of pharmacological relevance.
线粒体通透性转换孔(PTP)是一种内膜通道,其持续开放会导致线粒体功能障碍,并使PTP成为许多危及生命疾病的治疗靶点。在此,我们报告了通过构效关系优化研究来鉴定该靶点小分子抑制剂的工作,这导致在高通量筛选鉴定出的N-苯基苯甲酰胺化合物系列周围发现了几种强效类似物。特别是化合物4(3-(苄氧基)-5-氯-N-(4-(哌啶-1-基甲基)苯基)苯甲酰胺)在线粒体肿胀试验中表现出显著的抑制活性(EC50 = 280 nm),具有较差至非常好的物理化学性质以及体外药代动力学性质,并赋予线粒体非常高的钙保留能力。从这些数据来看,我们认为该系列中的化合物4是开发具有药理学相关性的PTP抑制剂的一个有前景的先导化合物。